Highest-materiality recent filing
LifeStance Q1 revenue up 21% to $403.5M; net income $14.2M; raises FY guidance
Revenue $403.5M (+21% YoY); net income $14.2M vs $0.7M; Adjusted EBITDA $51.1M (+48%).
Offering of 25,000,000 shares of common stock by selling stockholders; company receives no proceeds.
LifeStance Q4 revenue $382M (+17% YoY); net income $11.7M; $100M buyback; Chairman transition
Q4 revenue $382.2M (+17% YoY); full-year revenue $1.42B (+14% YoY).
Revenue $363.8M vs $312.7M YoY (+16%); net income $1.1M vs net loss of $6.0M.
LifeStance Q2 revenue $345.3M (+11% YoY); raises FY 2025 Adj. EBITDA guidance to $140-150M
Revenue of $345.3M (+11% YoY); net loss narrowed to $3.8M from $23.3M.
LifeStance Q1 revenue $333M (+11%), first positive net income as public company
Revenue $333M (+11% YoY); net income $0.7M vs net loss $21.1M in Q1 2024.
LifeStance Q4 revenue $325.5M (+16% YoY); 2025 EBITDA guidance $130-150M
Q4 revenue $325.5M (+16% YoY); full year $1.251B (+19% YoY).
Dave Bourdon, CFO since 2022, becomes CEO effective March 3, 2025; Ryan McGroarty appointed CFO effective March 17, 2025.
LifeStance Q3 revenue $312.7M (+19% YoY); raises FY2024 guidance on Adj. EBITDA to $105-115M
Revenue $312.7M (+19% YoY); net loss improved to $6.0M from $61.6M; Adjusted EBITDA $30.7M (+110%).
LifeStance Q2 revenue up 20% to $312M; raises FY2024 guidance on strong margins
Revenue $312.3M (+20% YoY); net loss narrowed to $23.3M from $45.5M; Adjusted EBITDA $28.6M (+103%).
Underwriting agreement signed May 21 for 20M shares (plus 3M option) sold by selling stockholders.
LifeStance Q1 revenue +19% to $300.4M; raises FY2024 EBITDA guidance; COO to depart June 30
Q1 revenue $300.4M (+19% YoY); net loss narrowed to $21.1M from $34.2M.
LifeStance Q4 revenue $280.6M (+22% YoY); net loss $45M; guides FY24 revenue $1.19-$1.24B
Q4 revenue $280.6M (+22% YoY); full-year revenue $1,055.7M (+23%).
LifeStance receives final court approval for $50M settlement; pays second $25M early
Final approval granted Jan 30, 2024 for $50M class action settlement (Nayani v. LifeStance).
LifeStance Q3 revenue up 21% to $262.9M, net loss widens to $61.6M, raises FY guidance midpoints
Revenue $262.9M (+21% YoY); clinicians up 18% to 6,418 with record organic recruiting.
LifeStance Q2 revenue up 24% to $259.6M; raises FY revenue guidance to $1.01-1.04B
Q2 revenue $259.6M (+24% YoY); net loss $45.5M improved from $68.7M loss.
LifeStance Q1 rev $252.6M (+24% YoY), net loss narrows to $34.2M; raises FY rev guidance
Revenue $252.6M (+24% YoY); Center Margin $69.6M (27.6% of revenue, +28% YoY).
LifeStance Q4 revenue $229.4M (+21% YoY); net loss $46.7M; 2023 rev guidance $980M-$1.02B
Q4 revenue $229.4M (+21% YoY), full year revenue $859.5M (+29% YoY).
Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).
LifeStance appoints David Bourdon as CFO, J. Michael Bruff to Business Transformation Officer
David Bourdon appointed CFO effective Nov 10, 2022; succeeds J. Michael Bruff who becomes Business Transformation Officer.
LifeStance appoints Ken Burdick as CEO/Chairman; founding CEO Michael Lester retires
Ken Burdick appointed CEO and Chairman effective Sept 7, 2022; succeeds Michael Lester who retires as officer and director.
Revenue $209.5M, +31% YoY; net loss $68.7M (incl $57.5M stock comp).
LifeStance COO Gwen Booth retiring July 1, 2022; Danish Qureshi promoted to succeed her
Gwen Booth retires as COO effective July 1, 2022; will consult for $13,750/month and lead LifeStance Health Foundation.
LifeStance Q1 rev +42% to $203.1M, net loss $62.3M on stock comp; reaffirms FY guidance
Revenue $203.1M (+42% YoY); net loss $62.3M (vs. $8.7M loss) driven by $59.9M stock-based comp.
LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed
Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.
Revenue $173.8M, up 70% YoY; Center Margin $52.1M (29.9% of revenue), up 57%.
LifeStance Health Q2 revenue $160.5M (+91% YoY), initiates FY2021 guidance
Revenue $160.5M, up 91% YoY; net loss $70M includes $29.5M stock comp and $10M foundation endowment.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
On July 2, 2026, Jeffrey Rhodes notified the LifeStance Health Group, Inc. (the “Company”) board of directors (the “Board”) of his resignation from the Board and all of its committees, effective immediately.
The Company appointed Vaughn Paunovich to serve as the Company’s new Chief Technology Officer, effective as of June 9, 2025.
On May 14, 2025, LifeStance Health Group, Inc. (the “Company”) announced that, effective July 1, 2025 (the “Transition Date”), Pablo Pantaleoni, the Company’s Chief Digital Officer will be leaving the Company.
Mr. Bourdon will succeed Kenneth Burdick, who has served as the Company’s Chief Executive Officer since 2022 and who is retiring from his position, effective as of the CEO Start Date.
promoted David Bourdon to serve as the Company’s Chief Executive Officer effective as of March 3, 2025
the Board of Directors also appointed Ryan McGroarty as the Company’s Chief Financial Officer and Treasurer, effective as of March 17, 2025
Effective as of June 30, 2024 (the “Separation Date”), Danish Qureshi’s employment as President and Chief Operating Officer of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) terminated.
On May 6, 2024, Danish Qureshi, the President and Chief Operating Officer of LifeStance Health Group, notified the Company of his decision to depart the Company, effective June 30, 2024.
On March 12, 2024, the Company’s Board of Directors (the “Board”) appointed Teresa DeLuca as a director of the Company, effective immediately.
Max materiality 0.85 · Median 0.68 · Most common event earnings